A Randomized, Double-blind, Parallel-group, Multicenter, Pharmacokinetic Study Comparing Weekly Intravenous Administration of OctaAlpha1 (Octapharma) With a Marketed Preparation Glassia (Kamada Ltd.) in Subjects With Alpha-1-antitrypsin Deficiency

Trial Profile

A Randomized, Double-blind, Parallel-group, Multicenter, Pharmacokinetic Study Comparing Weekly Intravenous Administration of OctaAlpha1 (Octapharma) With a Marketed Preparation Glassia (Kamada Ltd.) in Subjects With Alpha-1-antitrypsin Deficiency

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs OctaAlpha1 (Primary) ; Alpha 1-antitrypsin
  • Indications Alpha 1-antitrypsin deficiency
  • Focus Pharmacokinetics
  • Sponsors Octapharma
  • Most Recent Events

    • 06 Apr 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 05 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top